Detection of mitochondrial DNA variants at low level heteroplasmy in pediatric CNS and extra-CNS solid tumors with three different enrichment methods.
Central Nervous System
/ pathology
Central Nervous System Neoplasms
/ genetics
DNA, Mitochondrial
/ genetics
Genetic Variation
/ genetics
Genome, Mitochondrial
/ genetics
Heteroplasmy
/ genetics
High-Throughput Nucleotide Sequencing
/ methods
Humans
Mitochondria
/ genetics
Nucleic Acid Amplification Techniques
/ methods
Polymerase Chain Reaction
/ methods
AT/RT
Brain tumor
CNS tumor
Mitochondria
Pediatric cancer
Retinoblastoma
Rhabdoid tumor
Rhabdomyosarcoma
Sarcoma
Journal
Mitochondrion
ISSN: 1872-8278
Titre abrégé: Mitochondrion
Pays: Netherlands
ID NLM: 100968751
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
28
09
2019
revised:
28
11
2019
accepted:
08
01
2020
pubmed:
24
1
2020
medline:
24
2
2021
entrez:
24
1
2020
Statut:
ppublish
Résumé
The mitochondrial genome is small, 16.5 kb, and yet complex to study due to an abundance of mitochondria in any given cell or tissue. Mitochondrial DNA (mtDNA) mutations have been previously described in cancer, many of which were detected at low heteroplasmy. In this study we enriched the mitochondrial genome in primary pediatric tumors for detection of mtDNA variants. We completed mtDNA enrichment using REPLI-g, Agilent SureSelect, and long-range polymerase chain reaction (LRPCR) followed by next generation sequencing (NGS) on Illumina platforms. Primary tumor and germline genomic DNA from a variety of pediatric central nervous system (CNS) and extra-CNS solid tumors were analyzed by the three different methods. Although all three methods performed equally well for detecting variants at high heteroplasmy or homoplasmy, only LRPCR and SureSelect-based enrichment methods provided consistent results for variants that were present at less than five percent heteroplasmy. We then applied both LRPCR and SureSelect to three successive samples from a patient with multiply-recurrent gliofibroma and detected a low-level novel mutation as well as a change in heteroplasmy levels of a synonymous variant that was correlated with progression of disease. IMPLICATION: This study demonstrates that LRPCR and SureSelect enrichment, but not REPLI-g, followed by NGS are accurate methods for studying the mtDNA variations at low heteroplasmy, which may be applied to studying mtDNA mutations in cancer.
Identifiants
pubmed: 31972374
pii: S1567-7249(19)30233-8
doi: 10.1016/j.mito.2020.01.006
pmc: PMC7502000
mid: NIHMS1616945
pii:
doi:
Substances chimiques
DNA, Mitochondrial
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
97-103Subventions
Organisme : NCI NIH HHS
ID : R01 CA137124
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009659
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Gen Physiol. 1927 Mar 7;8(6):519-30
pubmed: 19872213
PLoS Genet. 2015 Jun 30;11(6):e1005333
pubmed: 26125550
JCO Precis Oncol. 2019;3:
pubmed: 31179415
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Elife. 2019 Feb 18;8:
pubmed: 30775970
Cancer Res. 2003 Jul 15;63(14):3866-71
pubmed: 12873974
Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2):
pubmed: 30755392
Cell Res. 2009 Jul;19(7):802-15
pubmed: 19532122
Oncogene. 2006 Aug 7;25(34):4647-62
pubmed: 16892079
Cell Res. 2018 Mar;28(3):281-295
pubmed: 29424373
BMC Genomics. 2017 Apr 26;18(1):326
pubmed: 28441938
Elife. 2014 Oct 01;3:
pubmed: 25271376
Cell. 2016 Jul 28;166(3):555-566
pubmed: 27471965
Front Genet. 2019 Jan 25;9:718
pubmed: 30740126
J Pediatr Hematol Oncol. 2010 Mar;32(2):156-9
pubmed: 20147852
PLoS One. 2007 Aug 01;2(8):e681
pubmed: 17668059
Cell Res. 2018 Mar;28(3):265-280
pubmed: 29219147
Ann Lab Med. 2016 Mar;36(2):101-10
pubmed: 26709256
Curr Genet Med Rep. 2018 Jun;6(2):62-72
pubmed: 30393588
Clin Chem. 2012 Sep;58(9):1322-31
pubmed: 22777720
Oncotarget. 2016 Feb 9;7(6):6620-5
pubmed: 26735174
Front Cell Dev Biol. 2017 Apr 19;5:37
pubmed: 28470001
PLoS Med. 2005 Nov;2(11):e296
pubmed: 16187796
Mol Neurobiol. 2015 Dec;52(3):1341-1363
pubmed: 25341474
Cancer Prev Res (Phila). 2010 Sep;3(9):1205-11
pubmed: 20660573
Cancer Res. 2019 Apr 1;79(7):1318-1330
pubmed: 30709931
J Biol Chem. 2017 Aug 18;292(33):13500-13506
pubmed: 28687630
Cold Spring Harb Perspect Biol. 2013 Nov 01;5(11):a021220
pubmed: 24186072
Nat Rev Cancer. 2012 Oct;12(10):685-98
pubmed: 23001348
Oncogene. 2006 Aug 7;25(34):4663-74
pubmed: 16892080
Discov Med. 2012 Dec;14(79):389-99
pubmed: 23272691